[Form 4] Organon & Co. Insider Trading Activity

Rhea-AI Filing Summary

Organon & Co. reported an equity grant to a senior officer through a Form 4 filing. Interim Head of Manufacturing & Supply Juliana Drinane received an award of 65,616 restricted stock units (RSUs) on November 13, 2025. Each RSU converts into one share of Organon common stock, so this grant represents 65,616 potential future shares. The RSUs will vest in three equal installments on November 13, 2026, November 13, 2027, and November 13, 2028, aligning the officer’s compensation with the company’s longer-term performance.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Drinane Juliana Papa

(Last) (First) (Middle)

C/O ORGANON &CO.

30 HUDSON STREET, FLOOR 33

(Street)

JERSEY CITY NJ 07302

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Organon & Co. [ OGN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Interim Head of Mfg & Supply

3. Date of Earliest Transaction (Month/Day/Year)
11/13/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	11/13/2025		A		65,616		(2)	(2)	Common Stock	65,616	$0	65,616	D

Explanation of Responses:

1. Each Restricted Stock Unit ("RSU") converts into one share of Organon & Co. common stock.

2. The Reporting Person was granted RSUs, which represent a contingent right to receive one share of Organon common stock for each RSU. On November 13, 2025, RSUs were granted and will vest in three equal installments on each of November 13, 2026, November 13, 2027, and November 13, 2028.

Remarks:

	/s/ Faye C. Brown, as Attorney-in-Fact for Juliana Drinane	11/17/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Organon (OGN) disclose in this Form 4?

The filing shows that Interim Head of Manufacturing & Supply Juliana Drinane received a grant of 65,616 restricted stock units (RSUs) of Organon & Co. common stock on November 13, 2025.

How do the Organon (OGN) RSUs granted to the officer work?

Each restricted stock unit converts into one share of Organon common stock, giving the reporting person the right to receive the underlying shares if vesting conditions are met.

When do the 65,616 Organon (OGN) RSUs vest?

The 65,616 RSUs granted on November 13, 2025 will vest in three equal installments on November 13, 2026, November 13, 2027, and November 13, 2028.

Who is the reporting person in this Organon (OGN) Form 4 filing?

The reporting person is Juliana Drinane, who serves as Organon & Co.'s Interim Head of Manufacturing & Supply.

What type of securities are reported in the Organon (OGN) Form 4 table?

The filing reports restricted stock units (RSUs) as derivative securities, each representing the right to receive one share of Organon & Co. common stock.

Was the Organon (OGN) RSU award reported as directly owned?

Yes. The Form 4 indicates that the 65,616 restricted stock units are held with direct (D) ownership by the reporting person.